OncoCyte (OCX) Reports Q3 Loss, Lags Revenue Estimates

Published on November 9, 2021

OncoCyte (OCX) delivered earnings and revenue surprises of -57.14% and -69.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Continue reading on website
Other news

Inhibrx, Inc. (INBX) Reports Q3 Loss, Tops Revenue Estimates

November 9, 2021
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 5.26% and 153.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the...

Scientific Games (SGMS) Surpasses Q3 Earnings Estimates

November 10, 2021
Scientific Games (SGMS) delivered earnings and revenue surprises of 113.33% and -29.04%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the...